Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chi-Yi Chen

Showing results (61-70 of 132) with videos related to

Pageof 14
Sort By:
Gut|October 9, 2024
Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis BDavid Z Pan, Cameron M Soulette, Abhishek Aggarwal, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|July 31, 2025
Switching to tenofovir alafenamide in virally-suppressed chronic hepatitis B patients with renal/hepatic impairment: Phase 2 study sub-analysis from TaiwanChun-Jen Liu, Young-Suk Lim, Chi-Yi Chen, et al.
The Lancet. Infectious Diseases|February 1, 2021
Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trialYao-Chun Hsu, Chi-Yi Chen, I-Wei Chang, et al.
Journal of Hepatology|October 5, 2024
Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infectionChen-Hua Liu, Pin-Nan Cheng, Yu-Jen Fang, et al.
Journal of Gastroenterology and Hepatology|April 2, 2019
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysisChen-Hua Liu, Yu-Lueng Shih, Sheng-Shun Yang, et al.
Alimentary Pharmacology & Therapeutics|February 21, 2025
Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral-Induced Cure of Hepatitis C Virus InfectionYu-Ping Chang, Ji-Yuh Lee, Chi-Yi Chen, et al.
Annals of Internal Medicine|February 21, 2023
Cold Versus Hot Snare Polypectomy for Small Colorectal Polyps : A Pragmatic Randomized Controlled TrialLi-Chun Chang, Chi-Yang Chang, Chi-Yi Chen, et al.
Journal of Gastroenterology|April 13, 2024
Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Yu-Jen Fang, et al.
Journal of Medical Virology|May 15, 2024
Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Ji-Yuh Lee, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 21, 2026
Safety, Tolerability, and Pharmacodynamics of GS-4224 in Healthy Participants and Participants With Chronic Hepatitis BEdward J Gane, Chi-Yi Chen, Cheng-Hao Tseng, et al.
Pageof 14

Showing results (61-70 of 132) with videos related to

Sort By:
Pageof 14
Gut|October 9, 2024
Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis BDavid Z Pan, Cameron M Soulette, Abhishek Aggarwal, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|July 31, 2025
Switching to tenofovir alafenamide in virally-suppressed chronic hepatitis B patients with renal/hepatic impairment: Phase 2 study sub-analysis from TaiwanChun-Jen Liu, Young-Suk Lim, Chi-Yi Chen, et al.
The Lancet. Infectious Diseases|February 1, 2021
Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trialYao-Chun Hsu, Chi-Yi Chen, I-Wei Chang, et al.
Journal of Hepatology|October 5, 2024
Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infectionChen-Hua Liu, Pin-Nan Cheng, Yu-Jen Fang, et al.
Journal of Gastroenterology and Hepatology|April 2, 2019
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysisChen-Hua Liu, Yu-Lueng Shih, Sheng-Shun Yang, et al.
Alimentary Pharmacology & Therapeutics|February 21, 2025
Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral-Induced Cure of Hepatitis C Virus InfectionYu-Ping Chang, Ji-Yuh Lee, Chi-Yi Chen, et al.
Annals of Internal Medicine|February 21, 2023
Cold Versus Hot Snare Polypectomy for Small Colorectal Polyps : A Pragmatic Randomized Controlled TrialLi-Chun Chang, Chi-Yang Chang, Chi-Yi Chen, et al.
Journal of Gastroenterology|April 13, 2024
Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Yu-Jen Fang, et al.
Journal of Medical Virology|May 15, 2024
Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Ji-Yuh Lee, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 21, 2026
Safety, Tolerability, and Pharmacodynamics of GS-4224 in Healthy Participants and Participants With Chronic Hepatitis BEdward J Gane, Chi-Yi Chen, Cheng-Hao Tseng, et al.
Pageof 14